LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 43

Search options

  1. Article ; Online: A Novel Enzymatic Hydrolysis Method for Urine Aldosterone Quantification: A Case for Reassessing Clinical Cut-Offs of Primary Aldosteronism.

    Yazdanpanah, Mehrdad / Delaney, Sarah R / Beriault, Daniel R

    Clinical chemistry

    2023  Volume 69, Issue 8, Page(s) 915–923

    Abstract: Background: Primary aldosteronism (PA) is a common endocrine cause of secondary hypertension. The aldosterone/renin ratio is an important tool for PA screening, and dynamic testing in serum or urine is used to confirm the diagnosis. While LC-MS/MS is ... ...

    Abstract Background: Primary aldosteronism (PA) is a common endocrine cause of secondary hypertension. The aldosterone/renin ratio is an important tool for PA screening, and dynamic testing in serum or urine is used to confirm the diagnosis. While LC-MS/MS is considered the gold standard for testing, there is significant interlaboratory variability between the extraction procedures, which can impact diagnostic interpretation. To help overcome this, we present a simple and accurate LC-MS/MS method for the quantification of both serum and urine aldosterone using a novel enzymatic hydrolysis procedure.
    Methods: Serum and urine aldosterone was extracted and measured by LC-MS/MS. Urine-conjugated aldosterone glucuronide was hydrolyzed using a genetically modified glucuronidase enzyme. The assay precision, accuracy, limit of quantification, recovery, and carryover were evaluated and the new assay cut-offs were proposed.
    Results: The liquid chromatography method allowed for adequate separation of the aldosterone peak from closely eluting peaks. Significant in vitro aldosterone loss was observed during acid-catalyzed hydrolysis of urine, which was corrected with the addition of the internal standard to the urine before the hydrolysis step. Glucuronidase catalyzed hydrolysis of urine aldosterone glucuronide displays good correlation with the corrected acid-catalyzed hydrolysis. Serum aldosterone showed good agreement with reference values and the consensus range reported for external quality assessment specimens.
    Conclusion: A simple, fast, and highly accurate method for the detection of serum and urine aldosterone has been developed. The proposed novel enzymatic procedure allows for short hydrolysis time and compensates for urine aldosterone loss during the hydrolysis step.
    MeSH term(s) Humans ; Chromatography, Liquid/methods ; Aldosterone ; Hydrolysis ; Glucuronides ; Tandem Mass Spectrometry/methods ; Hyperaldosteronism/diagnosis ; Glucuronidase
    Chemical Substances Aldosterone (4964P6T9RB) ; Glucuronides ; Glucuronidase (EC 3.2.1.31)
    Language English
    Publishing date 2023-06-04
    Publishing country England
    Document type Journal Article
    ZDB-ID 80102-1
    ISSN 1530-8561 ; 0009-9147
    ISSN (online) 1530-8561
    ISSN 0009-9147
    DOI 10.1093/clinchem/hvad065
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Pushing the New NIH LDL-Cholesterol Equation to Its Limits.

    Higgins, Victoria / Delaney, Sarah R / Beriault, Daniel R

    The journal of applied laboratory medicine

    2021  Volume 6, Issue 5, Page(s) 1384–1386

    MeSH term(s) Cholesterol ; Cholesterol, LDL ; Humans ; Risk Factors
    Chemical Substances Cholesterol, LDL ; Cholesterol (97C5T2UQ7J)
    Language English
    Publishing date 2021-09-08
    Publishing country England
    Document type Letter
    ISSN 2576-9456
    ISSN 2576-9456
    DOI 10.1093/jalm/jfab064
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Perplexingly High Tacrolimus Concentrations in a Renal Transplant Patient with HIV.

    Higgins, Victoria / Kapur, Bhushan M / Beriault, Daniel R / Delaney, Sarah R

    Clinical chemistry

    2022  Volume 68, Issue 6, Page(s) 765–768

    MeSH term(s) Graft Rejection ; HIV Infections/drug therapy ; Humans ; Immunosuppressive Agents/therapeutic use ; Kidney Transplantation ; Tacrolimus/therapeutic use
    Chemical Substances Immunosuppressive Agents ; Tacrolimus (WM0HAQ4WNM)
    Language English
    Publishing date 2022-06-01
    Publishing country England
    Document type Journal Article
    ZDB-ID 80102-1
    ISSN 1530-8561 ; 0009-9147
    ISSN (online) 1530-8561
    ISSN 0009-9147
    DOI 10.1093/clinchem/hvac062
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Overutilization in laboratory medicine: tackling the problem with quality improvement science.

    Beriault, Daniel R / Gilmour, Julie A / Hicks, Lisa K

    Critical reviews in clinical laboratory sciences

    2021  Volume 58, Issue 6, Page(s) 430–446

    Abstract: Overutilization of tests and treatments is a widespread problem in contemporary heath care, and laboratory medicine is no exception. It is estimated that 10-70% of laboratory tests may be unnecessary, with estimates in the literature varying depending on ...

    Abstract Overutilization of tests and treatments is a widespread problem in contemporary heath care, and laboratory medicine is no exception. It is estimated that 10-70% of laboratory tests may be unnecessary, with estimates in the literature varying depending on the situation and the laboratory test. Inappropriate use of laboratory tests can lead to further unnecessary testing, adverse events, inaccurate diagnoses, and inappropriate treatments. Altogether, this increases the risk of harm to a patient, which can be physical, psychological, or financial in nature. Overutilization in healthcare is driven by complex factors including care delivery models, litigious practice environments, and medical and patient culture. Quality improvement (QI) methods can help to tackle overutilization. In this review, we outline the global healthcare problem of laboratory overutilization, particularly in the developed world, and describe how an understanding of and application of quality improvement principles can help to address this challenge.
    MeSH term(s) Delivery of Health Care ; Humans ; Laboratories ; Quality Improvement
    Language English
    Publishing date 2021-03-11
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 280641-1
    ISSN 1549-781X ; 1040-8363 ; 0590-8191
    ISSN (online) 1549-781X
    ISSN 1040-8363 ; 0590-8191
    DOI 10.1080/10408363.2021.1893642
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: The problem with population data for the determination of ferritin lower reference interval limits.

    Parker, Michelle L / Sholzberg, Michelle / Yip, Paul M / Beriault, Daniel R

    Clinical biochemistry

    2021  Volume 92, Page(s) 86

    MeSH term(s) Adult ; Anemia, Iron-Deficiency/blood ; Anemia, Iron-Deficiency/diagnosis ; Biomarkers/blood ; Cohort Studies ; Female ; Ferritins/blood ; Ferritins/deficiency ; Humans ; Missed Diagnosis ; Premenopause/blood ; Quality of Life ; Reference Values
    Chemical Substances Biomarkers ; Ferritins (9007-73-2)
    Language English
    Publishing date 2021-03-26
    Publishing country United States
    Document type Letter
    ZDB-ID 390372-2
    ISSN 1873-2933 ; 0009-9120
    ISSN (online) 1873-2933
    ISSN 0009-9120
    DOI 10.1016/j.clinbiochem.2021.03.013
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Validating the NIH LDL-C equation in a specialized lipid cohort: Does it add up?

    Higgins, Victoria / Leiter, Lawrence A / Delaney, Sarah R / Beriault, Daniel R

    Clinical biochemistry

    2021  Volume 99, Page(s) 60–68

    Abstract: ... Ultracentrifugation LDL-C more strongly correlated with NIH-calculated LDL-C (r: Conclusions: We validated the NIH ...

    Abstract Background: Guideline recommendations for the management of lipids in patients at risk for cardiovascular disease is largely based on low-density lipoprotein cholesterol (LDL-C) concentration. LDL-C is commonly calculated by the Friedewald equation, which has many limitations. The National Institutes of Health (NIH) equation better estimates LDL-C, particularly in patients with hypertriglyceridemia and/or low LDL-C. We validated the NIH LDL-C equation at the first Canadian clinical laboratory to implement this equation.
    Methods: A total of 3161 lipid ultracentrifugation results from a specialized lipid cohort of 2836 patients were included. LDL-C was calculated using the NIH and Friedewald equations and compared to LDL-C measured by ultracentrifugation. We determined the accuracy of these equations at treatment thresholds and developed NIH equation restriction criteria to ensure only accurate results are reported.
    Results: Ultracentrifugation LDL-C more strongly correlated with NIH-calculated LDL-C (r
    Conclusions: We validated the NIH equation against ultracentrifugation in a cohort with a wide lipid concentration range, which supported its superiority over the Friedewald equation. We recommend clinical implementing the NIH equation for all patients except those with type III hyperlipoproteinemia or TG > 9.04 mmol/L, with an LDL-C lower reporting limit of <0.50 mmol/L.
    MeSH term(s) Adolescent ; Adult ; Aged ; Aged, 80 and over ; Cholesterol, LDL/blood ; Female ; Humans ; Hyperlipoproteinemia Type III/blood ; Hypertriglyceridemia/blood ; Male ; Middle Aged ; National Institutes of Health (U.S.) ; Ultracentrifugation ; United States
    Chemical Substances Cholesterol, LDL
    Language English
    Publishing date 2021-10-14
    Publishing country United States
    Document type Journal Article ; Validation Study
    ZDB-ID 390372-2
    ISSN 1873-2933 ; 0009-9120
    ISSN (online) 1873-2933
    ISSN 0009-9120
    DOI 10.1016/j.clinbiochem.2021.10.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: The Present and Future of Lipid Testing in Cardiovascular Risk Assessment.

    White-Al Habeeb, Nicole M A / Higgins, Victoria / Wolska, Anna / Delaney, Sarah R / Remaley, Alan T / Beriault, Daniel R

    Clinical chemistry

    2023  Volume 69, Issue 5, Page(s) 456–469

    Abstract: Background: Lipids play a central role in the pathogenesis of cardiovascular disease (CVD), a leading cause of morbidity and mortality worldwide. Plasma lipids and lipoproteins are routinely measured to help identify individuals at high risk of ... ...

    Abstract Background: Lipids play a central role in the pathogenesis of cardiovascular disease (CVD), a leading cause of morbidity and mortality worldwide. Plasma lipids and lipoproteins are routinely measured to help identify individuals at high risk of developing CVD and to monitor patients' response to therapy. The landscape of lipid testing is rapidly changing, including new ways to estimate traditional lipid parameters (e.g., low-density lipoprotein-cholesterol [LDL-C] calculations) and new lipid parameters that show superiority for risk prediction (e.g., non-high-density lipoprotein-cholesterol [non-HDL-C], apolipoprotein B [apoB], and lipoprotein a [Lp(a)]).
    Content: Various national guidelines for managing dyslipidemia to prevent CVD are available, which primarily focus on LDL-C for identifying those at high risk and setting thresholds for optimal response to therapy. However, LDL-C can be calculated and measured in various ways, each with advantages and disadvantages. Importantly, the recently established Sampson-NIH LDL-C equation appears to be superior to preceding calculations, as is clear from the literature and in guidelines. There is now a shift towards using lipid parameters other than LDL-C, such as non-HDL-C, apoB, and Lp(a), to identify high-risk patients and/or establish treatment targets.
    Summary: The goal of this review is to discuss the present and future of lipid testing for CVD risk assessment through describing various national clinical guidelines, critically reviewing methods to calculate and measure LDL-C and discussing the clinical utility of additional lipid parameters.
    MeSH term(s) Humans ; Cardiovascular Diseases/diagnosis ; Cardiovascular Diseases/prevention & control ; Cholesterol, LDL ; Risk Factors ; Cholesterol ; Risk Assessment ; Apolipoproteins B ; Lipoproteins ; Heart Disease Risk Factors ; Cholesterol, HDL
    Chemical Substances Cholesterol, LDL ; Cholesterol (97C5T2UQ7J) ; Apolipoproteins B ; Lipoproteins ; Cholesterol, HDL
    Language English
    Publishing date 2023-03-31
    Publishing country England
    Document type Review ; Journal Article ; Research Support, N.I.H., Intramural
    ZDB-ID 80102-1
    ISSN 1530-8561 ; 0009-9147
    ISSN (online) 1530-8561
    ISSN 0009-9147
    DOI 10.1093/clinchem/hvad012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Canadian Society of Clinical Chemists Harmonized Pediatric Lipid Reporting Recommendations for Clinical Laboratories.

    Higgins, Victoria / White-Al Habeeb, Nicole M A / Bailey, Dana / Beriault, Daniel R / Blasutig, Ivan M / Collier, Christine P / Venner, Allison A / Adeli, Khosrow

    The Canadian journal of cardiology

    2024  

    Abstract: Detecting dyslipidemia early is important because atherosclerosis originates in childhood and early treatment can improve outcomes. In 2022, CCS/CPCA published a Clinical Practice Update to detect, evaluate, and manage pediatric dyslipidemia. However, ... ...

    Abstract Detecting dyslipidemia early is important because atherosclerosis originates in childhood and early treatment can improve outcomes. In 2022, CCS/CPCA published a Clinical Practice Update to detect, evaluate, and manage pediatric dyslipidemia. However, guidance on its translation into clinical laboratories is lacking. The Canadian Society of Clinical Chemists (CSCC) Working Group on Reference Interval Harmonization (hRI-WG) Lipid Team aims to aid guideline implementation and promote harmonized pediatric lipid reporting across Canada. The 2022 CCS/CPCA Clinical Practice Update, 2011 NHLBI Integrated Guidelines, and new data analysis (Canadian pediatric reference values from the Canadian Laboratory Initiative on Pediatric Reference Intervals (CALIPER) and retrospective patient data from large community laboratories) were incorporated to develop five key recommendations. These include recommendations to 1) offer both non-fasting and fasting lipid testing; 2) offer a lipid panel including total cholesterol, LDL-C, HDL-C, non-HDL-C and triglycerides, with ApoB and Lp(a) available as individually orderable tests; 3) flag total cholesterol, LDL-C, and non-HDL-C results ≥95th percentile, and HDL-C results <10th percentile, as recommended by CCS/CPCA/NHLBI and validated by CALIPER, and flag ApoB and non-fasting triglyceride results ≥95th percentile based on CALIPER, and do not flag Lp(a) results but mention the adult cut-off in the interpretive comments; 4) implement interpretive comments listed in the current report; and 5) implement the NIH LDL-C equation. The CSCC hRI-WG Lipid Team will support clinical laboratories to implement these recommendations using knowledge translation strategies. Harmonizing pediatric lipid reporting across Canadian clinical laboratories will optimize clinical decision-making and improve cardiovascular risk management in youth.
    Language English
    Publishing date 2024-02-07
    Publishing country England
    Document type Practice Guideline
    ZDB-ID 632813-1
    ISSN 1916-7075 ; 0828-282X
    ISSN (online) 1916-7075
    ISSN 0828-282X
    DOI 10.1016/j.cjca.2024.01.023
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Validating thyroid-stimulating hormone (TSH) reflexive testing cutpoints in a tertiary care institution.

    Taher, Jennifer / Brinc, Davor / Gilmour, Julie A / Beriault, Daniel R

    Clinical chemistry and laboratory medicine

    2019  Volume 58, Issue 1, Page(s) e11–e13

    MeSH term(s) Tertiary Healthcare ; Thyroid Function Tests ; Thyroid Gland ; Thyrotropin
    Chemical Substances Thyrotropin (9002-71-5)
    Language English
    Publishing date 2019-07-24
    Publishing country Germany
    Document type Letter ; Comment
    ZDB-ID 1418007-8
    ISSN 1437-4331 ; 1434-6621 ; 1437-8523
    ISSN (online) 1437-4331
    ISSN 1434-6621 ; 1437-8523
    DOI 10.1515/cclm-2019-0396
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Drug checking services as a surveillance tool for clinical laboratories: Examining trends in the unregulated fentanyl supply.

    Delaney, Sarah R / Konforte, Danijela / Stefan, Cristiana / Palaty, Jan / Sun, Difei / McDonald, Karen / Thompson, Hayley / Werb, Dan / Beriault, Daniel R

    Clinical biochemistry

    2022  

    Abstract: Objectives: Timely assessment and understanding of drug trends is essential for clinical laboratories to effectively respond to the overdose epidemic. In this proof-of-concept study, we sought to determine whether information obtained through Toronto's ... ...

    Abstract Objectives: Timely assessment and understanding of drug trends is essential for clinical laboratories to effectively respond to the overdose epidemic. In this proof-of-concept study, we sought to determine whether information obtained through Toronto's Drug Checking Services (DCS) and cross-provincial urine drug testing (UDT) data can be used as a surveillance tool for clinical laboratories and discuss the value of collaboration between the clinical laboratory, clinicians, and community partners to optimize patient care.
    Design & methods: Mass spectrometry-based UDT data from LifeLabs Ontario (n = 127,529) and British Columbia (n = 14,848), and drug checking data from Toronto DCS (n = 3,308 drugs or used paraphernalia) was collected between August 2020 and October 2021. Fentanyl co-positivity with toxic adulterants such as benzodiazepine-related drugs and fentanyl analogues were examined.
    Results: The percent co-positivity of fentanyl with etizolam, flualprazolam, flubromazolam, carfentanil, and acetylfentanyl in both Ontario UDT and DCS drugs/used paraphernalia showed similar trends. Regional differences in co-positivity with etizolam and fentanyl analogues were noted between Ontario and British Columbia UDT with patterns consistent over the entire 15-month collection period.
    Conclusions: Clinical laboratories should connect with their local DCS, if available, to understand and monitor unregulated drug trends. These data can be used as an important tool to help clinical laboratories tailor their UDT menus and thereby provide a community-focused service to improve patient care.
    Language English
    Publishing date 2022-11-12
    Publishing country United States
    Document type Journal Article
    ZDB-ID 390372-2
    ISSN 1873-2933 ; 0009-9120
    ISSN (online) 1873-2933
    ISSN 0009-9120
    DOI 10.1016/j.clinbiochem.2022.11.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top